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Abstract
Introduction: It is common for patients to switch between several healthcare providers. In this context, the long-term follow-up of medical condi-
tions based on laboratory test results obtained from different laboratories is a challenge. The measurement uncertainty in an inter-laboratory con-
text should also be considered in data mining research based on routine results from randomly selected laboratories. As a proof-of-concept study, 
we aimed at estimating the inter-laboratory reference change value (IL-RCV) for exemplary analytes from publicly available data on external quality 
assessment (EQA) and biological variation.
Materials and methods: External quality assessment data of the Reference Institute for Bioanalytics (RfB, Bonn, Germany) for serum creatinine, 
calcium, aldosterone, PSA, and of whole blood HbA1c from campaigns sent out in 2019 were analysed. The median CVs of all EQA participants were 
calculated based on 8 samples from 4 EQA campaigns per analyte. Using intra-individual biological variation data from the EFLM database, positive 
and negative IL-RCV were estimated with a formula based on log transformation under the assumption that the analytes under examination have a 
skewed distribution.
Results: We estimated IL-RCVs for all exemplary analytes, ranging from 13.3% to 203% for the positive IL-RCV and - 11.8% to - 67.0% for the nega-
tive IL-RCV (serum calcium - serum aldosterone), respectively.
Conclusion: External quality assessment data together with data on the biological variation – both freely available – allow the estimation of in-
ter-laboratory RCVs. These differ substantially between different analytes and can help to assess the boundaries of interoperability in laboratory 
medicine.
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Introduction
A major objective of laboratory medicine is stand-
ardization, which is intended to enable the inter-
operability of results from different test sites (1,2). 
This is essential for both the development and ap-
plication of clinical algorithms with decision limits 
based on laboratory values and for the long-term 
follow-up of patients with chronic diseases. Simi-
larly, interoperability of laboratory results is a ma-
jor challenge for scientific investigations that rely 
on unselected and not individually traceable rou-
tine data (e.g., big data approach). Especially the 
implementation of universal standards for identi-
fying medical laboratory observations in electron-
ic records, such as the Logical Observation Identi-
fiers Names and Codes (LOINC) code system, has 
fuelled the mining of lab data (3).
Discrepancies in values due to insufficient stand-
ardization can in principle be compensated by the 
determination of method-specific reference val-
ues; for scientific applications, the evaluation can 
then, for example, be carried out as x-fold of a cer-
tain reference range value. However, this is cur-
rently not practiced for essential laboratory ana-
lytes. Indeed, clinical guidelines addressing ana-
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lytes such as prostate-specific antigen (PSA) or cre-
atinine do not consider possible methodological 
discrepancies at all (4,5).
So far, there is no comprehensive data available to 
assess the limits of interoperability of standard 
laboratory analytes. Results of external quality as-
sessment (EQA) schemes, some of which are pub-
licly available, are an attractive data source in this 
context.
Reference change values (RCV) or critical differ-
ences have become established for the estimation 
of a true intra-individual dynamic in the follow-up 
of a patient beyond the measurement uncertainty 
(6). The calculation of the RCV takes into account 
the analytical variation of the measurement of an 
analyte (CVA) and the intra-individual biological 
variation (CVI) of the respective analyte (7). The 
RCV indicates the percentage by which two se-
quential results of a patient must differ if an actual 
biological change in the concentration must be as-
sumed with a high degree of probability. The esti-
mation of RCVs in the current application assumes 
that follow-up measurements are done in one and 
the same laboratory under unchanged conditions.
The evaluations of EQA campaigns across all partici-
pants – without method-specific evaluations – can 
be used to estimate CVA in an inter-laboratory set-
ting. The database of the European Federation of 
Laboratory Medicine (EFLM) provides a good basis 
for the CVI to be assumed (8). Calculated inter-labo-
ratory RCV (IL-RCV) could in turn be used for a criti-
cal appraisal of inter-laboratory records as exploited 
in epidemiological and data mining studies (Figure 1).
The aim of the study was to provide a proof-of-
concept for the feasibility of estimating an IL-RCV 
from the above-mentioned data sources as a basis 
for assessing the interoperability of a particular an-
alyte and to reflect the limitations of this approach. 
We addressed five representative standard ana-
lytes from different biochemical classes.
Figure 1. Scheme of calculation of inter-laboratory reference change values. EQA analytical variation from participating clinical labo-
ratories and intra-individual biological variation (CVI) data can be used to calculate analyte-specific IL-RCV, which may be used for a 
comprehensive evaluation of combined inter-laboratory data sets from unselected laboratories with heterogenous measurement 
procedures, e.g., as typically extracted in data mining and epidemiological studies. IL-RCV – inter-laboratory reference change values. 
EQA – external quality assessment.  CVA – analytical variation. CVI – intra-individual biological variations.
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Materials and methods
Materials
External quality assessment data of the Reference 
Institute for Bioanalytics (Rfb, Bonn, Germany) 
were obtained from the freely accessible web re-
sources (9). Four EQA programs were distributed in 
four campaigns in 2019 (identification: KS 1-4 2019; 
HM 1-4 2019; TM 1-4 2019; GH 1-4 2019). The profi-
ciency test samples are lyophilized materials. Data 
sets were evaluated for the five analytes: serum 
calcium, creatinine, aldosterone, PSA, and whole 
blood haemoglobin A1c (HbA1c). For each EQA 
sample, the mean value of the concentrations 
found by the participants, the CV observed for 
each analyte and sample from the participants’ 
data (as total analytical CV, CVA), the number of 
participants in the respective campaign, and the 
number of different methods stated in the EQAs 
report were assessed.
The data on biological variation (within-subject 
BV, CVI) of the five exemplary analytes were taken 
from the respective database of the EFLM and, in 
the case of serum calcium, from a printed publica-
tion (8,10).
Methods
There are several ways to calculate the RCV (7). The 
traditional approach introduced by Harris and Ya-
saka is RCV = 21/2 x Zα x (CVA2 + CVI2)1/2 (11). This is 
used to calculate symmetrical limits of the RCV for 
analytes that follow a normal distribution, where 
Zα is defining the number of standard deviations 
appropriate for the probability.
Given that many laboratory analytes have skewed 
rather than normal distributions, the log-normal 
approach is typically considered the best ap-
proach to determining RCV values (12,13). Accord-
ingly, we applied the log-normal approach, de-
scribed by Fokkema et al. to calculate asymmetri-
cal limits for the positive (upward) and negative 
(downward) reference change values (RCVpos, 
RCVneg) with the following equation RCVpos/neg = 
100% x (exp (± Zα x 21/2 (SDA2 + SDI2)1/2 - 1) (14). The 
calculation of SDA2 is performed as SDA2 = ln 
(CVA2+1), while SDI2 is calculated as SDI2 = ln 
(CVI2+1).
In many clinical situations, decision-making is typi-
cally based on the assessment of a significant rise 
or fall of a target analyte. We, therefore, set Zα to 
1.96, leading to 95% probability (P < 0.05) that is 
regarded as significant. 
Results
For all five exemplary analytes, the estimation of 
an IL-RCV was found possible. The results are sum-
marized in Table 1. The range of IL-RCVs of the ana-
lytes investigated was considerable and RCVpos 
ranged from 13.3% to 203% and RCVneg from - 
11.8% to - 67.0% for serum calcium and aldoster-
one, respectively.
Discussion
We have shown that the estimation of IL-RCVs 
from publicly available EQA and intra-individual 
biological variation data is possible for essential 
laboratory analytes.
We observed very large differences for RCVpos and 
RCVneg between five exemplary analytes from dif-
ferent biochemical classes applying the formula 
for log-normal RCV calculation (14). While IL-RCV 
for serum calcium, creatinine, and whole blood 
HbA1c were found below 20%, the IL-RCV for se-
rum aldosterone must be assumed to be well 
above 150% for positive and 50% for negative 
changes. This means that if patient’s samples are 
sent to randomly selected laboratories for follow-
up testing, a real change in the concentration of 
the analyte in the biological system can only be 
assumed with a high degree of probability (95%) if 
the rise in values exceeds 203% in case of serum 
aldosterone. An increase of reported concentra-
tions below cannot be considered a real change 
within the limits of measurement uncertainty in a 
between-laboratory setting.
We recognize that our approach has some limita-
tions. External quality assessment samples are 
typically processed specimens (e.g., for virus inac-
tivation), which can lead to limitations regarding 
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commutability. Especially lyophilized control ma-
terials can show commutability problems and be-
have differently than patient samples. Accordingly, 
analytical variation values calculated from lyophi-
lized materials may not correspond to the analyti-
cal variation calculated on the basis of commuta-
ble material. It is therefore possible that the real IL-
RCV is lower than we observed when using exclu-
sively unprocessed single-donor material in EQA. 
Corresponding data should in principle be gener-
ated but are currently not publicly available.
The Biological Variation Data Critical Appraisal 
Checklist (BIVAC) regularly updates the biological 
variation data from the EFLM database from sys-
tematic reviews and published studies. Still, it 
must be taken into account that the determination 
of biological variation data is not always based on 
very large data sets and that it has uncertainties, 
given that published CVI may not necessarily 
match the investigated patient cohort (15).
Our procedure can be used to assess the measure-
ment uncertainty in epidemiological surveys and 
data mining studies, such as the Medical Informat-
ics Initiative Germany, when data from unselected 
laboratories are used (16). They allow an estima-
tion of the limits of interoperability of routine data 
collected with today’s heterogeneous standard 
procedures and kits and should be considered 
when interpreting corresponding combined data 
sets. Furthermore, IL-RCV may assist in the inter-
pretation of changes in patient serial results ob-
tained from different laboratories. For a more 
comprehensive assessment, multiple EQA 
schemes and accessions might be combined to es-
tablish a corresponding expanded data set for in-
ter-laboratory analytical variation.
A notable caveat in large-scale data mining stud-
ies is the usage of pooled data from multiple labo-
ratories. It must be emphasized that correspond-
ing IL-RCVs are not exact mathematical calcula-
tions that can be transferred to individual evalua-
tions without exception but are rather estimates 
that may be useful for critical appraisal, in particu-
lar of data mining studies.
We conclude that EQA data together with data on 
the biological variation – both freely available – al-
low the estimation of inter-laboratory RCVs. These 
differ substantially between different analytes and 
can help to assess the boundaries of interoperabil-
ity in laboratory medicine.
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Number of EQA 
participants**
Creatinine µmol/L 115 – 478 168 4.7 4.5 +19.7 / - 16.5 14 645
Calcium mmol/L 1.81 – 3.35 2.20 3.1 3.3 +13.3 / - 11.8 12 615
Aldosterone nmol/L 0.3 – 20.1 0.8 18.6 36.6 +203 / - 67.0 8 203
PSA µg/L 0 – 14.0 0.4 18.8 6.8 +73.1 / - 42.2 13 804
HbA1c mmol/mol 36.0 – 71.2 51.5 5.1 1.7 +16.1 / - 13.9 12 810
*Lowest/highest mean concentration observed in the four EQA campaigns and each two samples per analyte. †Median of 8 means 
observed in the four EQA campaigns and each two samples per analyte. ‡Median CV of all participants observed in the four 
EQA campaigns studied, each two samples (median of 8 CVs). §Biological variation according to EFLM data base and for serum 
calcium (8,10). ║RCV according to Fokkema et al. (14). ¶Mean number of methods in the four campaigns studied. **Mean number 
of participants per EQA scheme from four campaigns in 2019. PSA – prostate-specific antigen. HbA1c – haemoglobin A1c. CV – 
coefficient of variation. CVA – analytical variation of all participants. CVI – intra-individual biological variations. RCVpos/neg – positive 
(upward) and negative (downward) reference change values. EQA – external quality assessment. EFLM – European Federation of 
Clinical Chemistry and Laboratory Medicine.
Table 1. Estimation of inter-laboratory positive and negative reference change values for five exemplary analytes based on data 
from external quality assessment schemes
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